Skip to main content
. 2024 Nov 20;16(22):3885. doi: 10.3390/cancers16223885

Table 4.

Ongoing clinical trials of pan-KRAS direct small molecule inhibitor monotherapies.

Compound Mechanism of Action Clinical Trial Indication Phase of Study
RMC-6236 Pan-RAS inhibitor 1
PF-07934040 Pan-KRAS inhibitor
  • -

    Given alone or in combination with advanced solid malignancies (NCT06447662)

1
YL-17231 Pan-KRAS inhibitor 1